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Despite recent progress in the development of direct-acting antiviral agents against hepatitis C virus (HCV),more effective therapies
are still urgently needed.We and others previously identified three phenothiazine compounds as potentHCVentry inhibitors. In this
study, we show that phenothiazines inhibitHCVentry at the step of virus-host cell fusion, by intercalating into cholesterol-rich do-
mains of the targetmembrane and increasingmembrane fluidity. Perturbation of the alignment/packing of cholesterol in lipidmem-
branes likely increases the energy barrier needed for virus-host fusion. A screening assay based on the ability ofmolecules to selectively
increase the fluidity of cholesterol-richmembraneswas subsequently developed.One compound that emerged from the library screen,
topotecan, is able to very potently inhibit the fusion of liposomeswith cell culture-derivedHCV (HCVcc). These results yield new in-
sights intoHCV infection andprovide a platform for the identification of newHCV inhibitors.
Hepatitis C virus (HCV) infects at least 130 million peopleworldwide and is the major cause of chronic liver disease.
Infected patients are at risk of developing fibrosis, cirrhosis, and
liver cancer (1–3). Although HCV was identified in 1989, ad-
vances in treatment have been augmented since the development
of cell culture-grown HCV (HCVcc) in 2005 (4–6). No vaccine is
available, and the current treatment for HCV infection involves a
weekly injection of pegylated alpha interferon and a twice-daily
weight-based dose of ribavirin for 24 to 48weeks. This standard of
care is plagued by a long duration, limited efficacy, and serious
side effects (7). Although the recent addition of new direct-acting
antivirals (DAAs) targeting HCV NS3-4A protease—telaprevir
and boceprevir—to the anti-HCV therapeutic arsenal have im-
proved the cure rates, they must be used in combination with
interferon, as HCV has a remarkable ability to overcome a single
DAA. Telaprevir and boceprevir only work in patients infected
with genotype 1 HCV and are both not very effective in patients
who did not respond to pegylated interferon-ribavirin therapy
(8). In addition, both telaprevir and boceprevir appear to worsen
the already problematic side effects of the standard therapy, such
as rashes and anemia (9). Currently approved DAAs and most
molecules in the pipeline are protease inhibitors, nucleoside in-
hibitors, nonnucleoside inhibitors, and NS5A inhibitors (10). A
major obstacle in combating HCV is the low fidelity of the viral
replicationmachinery, enabling the virus to quickly develop resis-
tance (11). To date, ITX-5061 is the only inhibitor of HCV entry
that has entered clinical testing. ITX-5061 blocks a postbinding
step in the viral entry process by directly interacting with the entry
factor scavenger receptor B1 (SR-B1) (12). New DAAs targeting
entry steps critical to viral infection with additive potency when
combined with existing DAAs and exhibiting low cytotoxicity are
highly desirable.
HCV is an enveloped, positive-sense RNA virus belonging to
the Flaviviridae family. The 9.6-kb viral genome encodes a single
large polyprotein that is processed by viral and cellular proteases
to produce the virion structural proteins (core and glycoproteins
E1 and E2), P7, and nonstructural proteins (NS2, NS3, NS4A,
NS4B, NS5A, and NS5B). HCV infection involves multiple steps.
Viruses first attach to target cells via glycosaminoglycans and low-
density lipoprotein (LDL) receptors. After recruitment to the
membrane, HCV binds sequentially to entry factors involving SR-
B1, the tetraspanin CD81, the Niemann-Pick C1-like 1 (NPC1L1)
cholesterol (Cho) uptake receptor, and proteins of tight junctions,
i.e., CLDN1 and OCLD (13). HCV then enters cells at the tight
junction via clathrin-mediated endocytosis and fuses with the
host membrane in the late endosome. Progress in defining the
molecular mechanism of HCV entry raises the opportunity to
exploit new viral and host targets for therapeutic intervention.
Entry inhibitors have the potential to limit the expansion of the
infected cell reservoir, prevent reinfection after liver transplanta-
tion, and complement the many protease and polymerase inhibi-
tors currently under development. Although the discovery of
drugs targeting the entry stage is still in its infancy, antibodies
against SR-B1 (14), CD81 (15), and CLDN1 (16), as well as a
number of small-molecule inhibitors, have recently been devel-
oped and are able to effectively block HCV entry (17–24).
Phenothiazines are a group of nitrogen- and sulfur-containing
tricyclic compounds that were first synthesized by Bernthsen in
1883. Phenothiazines with dialkylaminoalkyl groups and small
groups substituted at positions 10 and 2, respectively, were found
to interact with the dopamine receptors and have exhibited valu-
able activities, such as neuroleptic, antiemetic, antihistaminic, an-
tipruritic, analgesic, and anthelmintic activities (25). To date,
more than 100 phenothiazines have been used in clinics to treat
psychotic disorders, and over 5,000 phenothiazine derivatives
Received 23 December 2012 Returned for modification 31 January 2013
Accepted 15 March 2013
Published ahead of print 25 March 2013
Address correspondence to Zhilei Chen, zchen4@tamu.edu.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/AAC.02593-12.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.02593-12











have been synthesized. Other receptors that can be modulated by
phenothiazines include histamine H1, adrenergic 1 and 2,
muscarinic (cholinergic), and serotonergic receptors (25). In ad-
dition to neurotransmitter receptors, phenothiazines have also
been reported to bind to calmodulin and block its calcium signal-
transduction activity, inhibit clathrin-coated pit formation, and
activate rynodine receptors (26). Antiviral and antimicrobial ac-
tivities have also been described for phenothiazines and related
compounds (27).
Our lab and others recently identified three phenothiazines—
fluphenazine, trifluoperazine, and prochlorperazine—as potent
HCV entry inhibitors (28, 29). In this work, we wanted to under-
stand the antiviral mode of action of this family of compounds,
which presumably inhibit HCV entry through a common mech-
anismof action. This informationwill assist in future endeavors to
identify new andmore potent inhibitors of HCV entry. We found
that phenothiazines inhibit the virus-cell fusion step of the HCV
life cycle by intercalating into the host cholesterol-richmembrane.
In the presence of phenothiazines, cholesterol-rich membranes
become more permeable to water molecules, leading to increased
membrane fluidity. We subsequently developed a high-through-
put screening assay. We screened a library of 2,752 compounds
and identified a molecule, topotecan, that dose-dependently in-
hibits HCVcc-liposome fusion. This study suggests that alteration
of target cholesterol-richmembrane fluidity may be a novel mode
for suppressing HCV entry and should facilitate the identification
of new HCV inhibitors with unique modes of action.
MATERIALS AND METHODS
Cells, plasmids, compounds, and reagents. Huh-7.5 cells and plasmids
encoding HIV Gag-Pol (30) and the envelope proteins of HCV H77/J6
(30) and vesicular stomatitis virus (VSV) were kindly provided by Charles
Rice (Rockefeller University, NY). HEK 293T cells were purchased from
Invitrogen (Carlsbad, CA). Trifluoperazine, prochlorperazine, mesorida-
zine, promazine, triflupromazine, and cis-flupentixol were purchased
from Sigma-Aldrich (St. Louis, MO). Chlorpromazine and thioridazine
were from MP Biomedicals (Solon, OH). Fluphenazine and bafilomycin
were from Alfa Aesar (Ward Hill, MA) and Axxora (San Diego, CA),
respectively. All phenothiazine compounds were dissolved in dimethyl
sulfoxide (DMSO) to a 10 mM stock concentration. Bafilomycin was dis-
solved in DMSO to a 250 M stock concentration. Laurdan and Prodan
fluorescent probes were purchased from Anaspec (Fremont, CA). Laur-
dan and Prodan were dissolved in methanol and DMSO to final concen-
trations of 0.5 mM and 10 mM, respectively. The human anti-CD81 JS81
monoclonal antibody (MAb) was obtained from BD Biosciences (San
Jose, CA). CellTiter-Glo luminescent cell viability assay kits and BioLux
Gaussia luciferase assay kits were purchased from Promega (Madison,
WI) and New England BioLabs (Ipswich, MA), respectively. The growth
medium for all cell cultureworkwasDulbecco’smodified Eagle’smedium
(DMEM) containing 4,500mg/liter glucose, 4.0mML-glutamine, and 110
mg/liter sodium pyruvate (Thermo Scientific HyClone, Logan, UT) sup-
plemented with 10% fetal bovine serum (Atlanta Biologicals, Law-
renceville, GA) and 1 nonessential amino acids (Thermo Scientific Hy-
Clone, Logan, UT). Dulbecco’s phosphate-buffered saline (DPBS) was
purchased fromThermo Scientific HyClone (Logan, UT). Octadecyl rho-
damine B chloride (R18) was purchased from Invitrogen (St. Aubin,
France), and all other lipids (99% pure) were from Avanti Polar Lipids
(Alabaster, AL).
Production of HCVcc and pseudotyped lentiviruses. The produc-
tion and titer determination of Jc1GlucHCVcc (31) inHuh-7.5 cells were
performed as previously described (28). Jc1 Gluc HCV contains the
Gaussia luciferase (Gluc) reporter gene between the HCV genes encoding
the p7 and NS2 proteins. Pseudotyped lentiviruses were produced by
cotransfecting 293T cells with plasmids encoding HIV Gag-Pol (30), a
provirus (pTRIP-Gluc) (28), and the appropriate envelope protein, using
TransIT reagent (Mirus,Madison,WI) following themanufacturer’s pro-
tocol. The supernatants containing the pseudoparticles were collected,
pooled, and filtered (0.45mpore size) at 48 h posttransfection and then
stored at 4°C for up to 1 week or at 80°C for long-term storage. For
production of lentiviruses pseudotyped with the envelope proteins from
HCV genotype 1a H77 (H77 HCVpp), HCV genotype 2b J6 (J6 HCVpp),
and vesicular stomatitis virus (VSV-Gpp), plasmids H77 E1E2 pcDNA3,
J6 E1E2 pcDNA3, and pVSVG, respectively, were used (30). A control
pseudotyped lentivirus lacking any envelope protein (Envpp) was gen-
erated using the same protocol, except that the envelope protein-encod-
ing plasmid was replaced with empty vector (pcDNA3).
HCVcc infection assays. To determine whether phenothiazines are
virucidal, Jc1 Gluc HCVcc (6.4  105 50% tissue culture infective doses
[TCID50]/ml) was incubated with phenothiazines (50 or 5 M), PD
404,182 (150 M), or DMSO (0.5%) for 1 h at 37°C, and the virus-
compoundmixtures were diluted 100-fold in growthmediumandused to
infect Huh-7.5 cells seeded 4 to 6 h earlier in 96-well plates at 3.2  104
cells/well. For controls, virus and drugs were diluted 100-fold separately
andmixed before infectingHuh-7.5 cells. Cells were thoroughlywashed at
14 to 16 h post-virus inoculation to remove residual drug and virus. Su-
pernatant Gluc activity was measured at 48 h postinfection. The percent-
ages of virus entry and spread were determined relative to those of the
DMSO control.
To determine whether phenothiazines act on host cells, Huh-7.5 cells
were infected with Jc1 Gluc HCVcc at various times after drug removal.
Briefly, Huh-7.5 cells were seeded in 48-well plates at 4  104 cells/well.
After attachment, these cells were treatedwith phenothiazines (5M), PD
404,182 (150M), bafilomycin (10 nM), orDMSO (0.5%) for 2 h at 37°C.
For sets 1 to 3, these cells were washed thoroughly to remove residual
drugs and then inoculated with Jc1 Gluc HCVcc (multiplicity of infection
[MOI]  1) or VSV-Gpp (100-fold dilution) at 0, 4, or 24 h post-drug
removal at 37°C. At 15 minutes post-virus inoculation, these cells were
thoroughly washed to remove any remaining viruses and returned to the
37°C and 5% CO2 incubator. For set 4, cells were infected with the same
viruses, but in the presence of the drug, and were continuously incubated
in drug-containing medium after the infection period. Supernatant Gluc
activity was measured at 72 h postinfection, normalized to viable cell
levels, and used as an indication of viral infection.
To determine the anti-HCV activities of phenothiazines (Table 1) and
topotecan (see Fig. 6C), Huh-7.5 cells (1.6 104 cells/well) seeded 4 to 6
h earlier were infectedwith Jc1GlucHCVcc (MOI 0.01) in the presence
of increasing concentrations of the compounds. SupernatantGluc activity
was measured at 48 to 72 h postinfection and normalized to the DMSO
(0.02 to 0.5%) treatment control. The cell viability was measured using
the CellTiter-Glo assay (Promega, Madison, WI) to gauge the compound
toxicity. The 50% inhibitor concentration (IC50), 50% effective concen-
tration (EC50), and 50% cytotoxic concentration (CC50) were calculated
using the sigmoidal fit function in OriginLab (OriginLab, Northamp-
ton, MA).
Synchronized HCVcc infection assay. To determine the step of entry
inhibited by phenothiazines, we carried out a synchronized infection as-
say (Fig. 1B). Huh-7.5 cells were seeded in 48-well plates at 4 104 cells/
well. The next day, virus-cell attachment was initiated by incubating the
cells with Jc1 Gluc HCVcc (MOI 1) at 4°C for 1.5 h. Unbound viruses
were removed by thorough washing with complete growth medium, and
then infection of bound viruses was initiated by moving the cell culture
plates to a 37°C and 5% CO2 incubator. Fluphenazine (5 M), bafilomy-
cin (10 nM), JS81 (2 g/ml), or DMSO (0.05%) was added to the cells at
different time points after the temperature shift. Cells were washed thor-
oughly with complete growth medium at 5 h post-drug addition. Super-
natant Gluc activity was measured at 48 h postinfection, using a BioLux
Gaussia luciferase assay kit (NewEnglandBioLabs, Ipswich,MA), andwas
used as an indication of viral infection.
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HCVpp/cc-liposome fusion assay. To evaluate the ability of com-
pounds to inhibit HCV fusion in vitro, we carried out an HCV-liposome
fusion assay. Fusion between HCVpp and liposomes was assayed as de-
scribed elsewhere (32). H77 HCVpp collected from the cell supernatant
was purified and concentrated 100-fold by use of ultracentrifugation de-
vices, to a titer of107 IU/ml. One microliter of liposomes (25 M final
lipid concentration) composed of phosphatidylcholine (PC), cholesterol,
and R18 (65:30:5 mol%) was added to a 37°C thermostated cuvette con-
taining 20 l concentrated H77 HCVpp (2  105 viral particles) in
phosphate-buffered saline (PBS) at pH7.2. Fluphenazine, trifluoperazine,
or promazine dissolved in DMSO was added to the mixture at a final
concentration of 2.5, 5, 10, or 20 M. After thermic equilibration, fusion
was initiated by adding 2l diluted HCl (final pH, 5.0). Lipid mixing was
measured as the dequenching of R18 (excitation, 560 nm; emission, 590
nm), resulting in an increase of the fluorescence signal. Recordings were
performed with a Tecan Infinite-1000 spectrofluorometer. Maximal R18
dequenching was measured after addition of Triton X-100 to the cuvette
at a 0.1% final concentration. Fusion between JFH-1 HCVcc and lipo-
somes was determined similarly. Freshly prepared JFH1 HCVcc, concen-
trated 100-fold through a 20% sucrose cushion, was used in the fusion
experiment (33).
For the modified HCVpp-liposome fusion experiment, 20 l concen-
trated H77 HCVpp or liposomes (working suspension at a 1:20 dilution
from stock) was preincubated with fluphenazine, trifluoperazine, or
promazine at a 5 M final concentration for 3 min at 37°C. This mixture
was then diluted 10-fold with PBS to reach a 0.5 M final drug concen-
tration, and 1l untreated liposomes or 20l HCVppwas added, respec-
tively. Fusion was determined in the same way as that described above.
The study of the effect of topotecan on HCVcc, membrane fusion was
performed as described previously (33). Briefly, JFH-1 HCVcc (1.6 
105 particles), suspended in 150 mM NaCl, 10 mM Tricine-NaOH, pH
7.4, was added to a cuvette containing R18-labeled PC-cholesterol lipo-
somes (15 M final lipid concentration) in the absence or presence of
increasing concentrations of topotecan. After temperature equilibration,
fusion was initiated by HCl addition to the cuvette, and kinetics were
recorded using a dual-channel PicoFluor handheld fluorometer (Turner
Biosystems, Sunnyvale, CA) operated under the “rhodamine” channel
(excitation and emission wavelengths of 540 20 and570 nm, respec-
tively). Maximal R18 dequenching was measured after the addition of
0.1% Triton X-100 (final concentration) to the cuvette.
Fluorescence spectroscopy. To determine whether phenothiazines
affect membrane fluidity, we calculated the generalized polarization (GP)
of the fluorescent dyes Laurdan and Prodan incorporated into the lipo-
somes in the absence or presence of phenothiazines. POPC (11-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine), sphingomyelin (SM), and cho-
lesterol (Cho) (Avanti Polar Lipids, Inc., Alabaster, AL) dissolved in
chloroform at 10 mg/ml were mixed at a molar ratio of 1:0:0 (100%
POPC), 2.3:0:1 (70% POPC plus 30%Cho), or 3.9:1:2.3 (54% POPC plus
14% SM plus 32% Cho). To remove solvent, the lipids were first dried
under a stream of nitrogen and then lyophilized. The lyophilized lipid
mixtureswere resuspended inDPBS at a 400Mfinal lipid concentration,
sonicated at room temperature in a water bath sonicator for 10 min, and
extruded repeatedly through a 100-nm polycarbonate membrane filter
(Avanti Polar Lipids, Inc.) to obtain uniformly sized liposomes. Extruded
liposomes were stored at 4°C for up to a week. For GP determination,
liposomes (200 M final concentration) were first incubated with Laur-
dan (5 M final concentration) or Prodan (15 M final concentration)
for 15 min at room temperature in the dark. Increasing concentrations of
the compounds were added to the mixture, and 100 l/well of liposome-
drug mixture was transferred to a white 384-well plate. The plate was
TABLE 1 Phenothiazines and thioxanthene used in this study, with their anti-HCV properties
Compound class
Compound
subclass Compound R group Structure IC50 (M)
a CC50 (M)
a CC50/IC50
Phenothiazines Aliphatics Chlorpromazine Cl 1.47 0.32 8.76 1.68 6
Aliphatics Promazine 2.28 0.43 12 5.3
Aliphatics Triflupromazine CF3 1.20 0.43 8.15 0.52 6.8
Piperidines Mesoridazine 1.77 1.01 12 6.8
Piperidines Thioridazine 0.78 0.31 5.28 0.84 6.8
Piperazines Prochlorperazine Cl 0.92 0.11 7.60 1.49 8.3
Piperazines Trifluoperazine CF3 0.69 0.13 6.29 0.61 9.1
Piperazines Fluphenazine 0.37 0.01 5.65 0.09 15.3
Thioxanthene cis-Flupentixol 0.25 0.07 5.22 0.23 20.9
a IC50 and CC50 values were calculated using a Gluc reporter HCVcc infection assay and represent averages standard deviations for two independent experiments.
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incubated at 23°C for 30 min in the dark, and fluorescence spectra were
collected in a Gemini EM spectrofluorometer (Molecular Devices, San
Francisco, CA) with an excitation wavelength of 310 to 350 nm for both
dyes and the emission spectra recorded at 440 and 480 nm for Prodan and
440 and 490nm for Laurdan.GPwas calculated according to the following
equation (34): GP (IB IR)/(IB	 IR), where IB and IR are the fluores-
cence intensities at the blue and red edges of the emission spectrum, re-
spectively. Data were corrected for the background signal measured with
liposomes deprived of a probe. After the fluorescence spectra were mea-
sured, the plate was returned to a 37°C incubator for another 30min, after
which the spectra were measured again.
Screen for inhibitors. A high-throughput screening assay was devel-
oped based on the ability of a compound to selectively increase the GP of
cholesterol-rich liposomes in comparison to the DMSO control. The li-
brary screening was conducted at The National Screening Laboratory for
the Regional Centers of Excellence in Biodefense and Emerging Infectious
Disease (NSRB). Liposomes composed of POPCalone or POPC,Cho, and
SMat a 3.9:1:2.3molar ratio (200Mfinal concentration)were incubated
with Prodan (15Mfinal concentration) for 15min at room temperature
in the dark. Eightymicroliters of themixture was dispensed into each well
of white 384-well plates by use of a Matrix WellMate liquid dispenser
(Matrix, Hudson, NH). One hundred nanoliters of the drug library (with
concentrations ranging from2 to 5mg/ml) was then added to eachwell by
use of a Seiko D-TRAN XM3106-31 PN 4-axis Cartesian robot pin trans-
feror (Caliper Life Science, Waltham, MA). The plates were incubated in
the dark for 30 min at room temperature, and the fluorescence spectra
were collected in an SGM 610 FlexStation III spectrofluorometer (Molec-
ular Devices, San Francisco, CA) with an excitation wavelength of 310 nm
and the emission spectra recorded at 440 and 480 nm. We screened the
Biomol4 (Enzo Life Sciences, Plymouth Meeting, PA) and Chembridge 3
libraries for molecules whose GP differed from that of the 0.25% DMSO
control by a value of 0.05 (positive hit). Although we screened only
2,752 compounds in this study, this assay is amenable to high-throughput
screening.
Replication inhibition and qRT-PCR. To determine the effect of
topotecan on viral replication, we quantified the amounts ofHCVRNA in
the appropriate cells (see Fig. 7A). Huh-7.5 cells were electroporated with
Jc1GlucHCV genomic RNA according to a previously described protocol
(28) and seeded into 24-well plates (1.4  105 cells/well). The desired
compounds were added to the medium at 6 h postelectroporation. The
medium was replaced with fresh, compound-containing medium at 48 h
postelectroporation, and the supernatant Gluc activity was determined
using a BioLux Gaussia luciferase assay kit (New England BioLabs, Ips-
wich, MA) at 72 h postelectroporation. After removing all the superna-
tant, these cells were washed once with Dulbecco’s phosphate-buffered
saline (Thermo Scientific HyClone, Logan, UT) and underwent one
freeze-thaw cycle at80°C before RNA extraction using an EZNA Total
RNA kit (Omega Bio-Tek, Norcross, GA). The amount of HCV RNAwas
quantified via TaqMan quantitative reverse transcription-PCR (qRT-
PCR) (qScript One-Step Fast kit; Quanta Biosciences, Gaithersburg,
MD), using previously described primers (35).
Virus entry inhibition assay. To determine the effect of topotecan on
HCV entry, uptake of HCVpp in the presence of the compound was eval-
uated. Huh-7.5 cells were seeded in poly-L-lysine-treated 96-well flat-bot-
tom tissue culture plates at 1.8 104 cells/well and incubated at 37°C and
5% CO2 for 5 to 6 h to allow cell attachment. Compounds were added to
the appropriate wells 1 h before transduction. HCVpp and Envpp were
added to the cells at a 1:5 dilution. The next day, these cells were washed 4
times with 100 l/well of complete growth medium to remove unbound
pseudoparticles and preexisting Gluc reporter, and 100 l of fresh me-
dium was added to each well. Supernatant Gluc activity was quantified at
48 h postwashing by use of a BioLux Gaussia luciferase assay kit (New
England BioLabs, Ipswich, MA). The presented HCVpp entry data repre-
FIG 1 Phenothiazines inhibit HCV fusion. (A) Schematic of synchronized HCVcc infection assay. Huh-7.5 cells were incubated with Jc1 Gluc HCVcc (MOI
1) for 1.5 h at 4°C, washed extensively, and shifted to 37°C. Fluphenazine (5M), bafilomycin (10 nM), JS81 (2g/ml), or DMSO (0.05%)was added at different
times after the temperature shift and removed at 5 h post-compound addition. Supernatant Gluc activity was measured at 48 h postinfection, normalized to the
DMSO control level, and used as an indication of infection efficiency. (B) Fluphenazine inhibits HCVcc entry at a step similar to that of bafilomycin inhibition
and later than JS81 inhibition. Fluphenazine (5 M), JS81 (2 g/ml), or bafilomycin (10 nM) was added to the appropriate wells at different times post-
temperature shift. Representative data from at least 5 independent experiments are presented. The error bars represent standard deviations for triplicate samples.
(C) In vitro liposome fusion assay confirms that fluphenazine, trifluoperazine, and promazine dose-dependently inhibit HCV fusion. ConcentratedH77HCVpp
(2 105 particles) wasmixedwithR18 dye-labeled liposomes and increasing concentrations of the phenothiazines. Fusion betweenHCVpp and liposomeswas
triggered by the addition of HCl to lower the solution pH. Dequenching of the R18 dye, corresponding to fusion betweenHCVpp and liposomes, wasmonitored
by determining the increase in fluorescence. The x axis corresponds to the duration of the fusion process. Curves representative of at least 4 independent
experiments are presented.
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sent differences in supernatant Gluc activities between HCVpp- and
Envpp-transduced cells at the specified compound concentrations.
Statistical analysis. Statistical significance between different samples
was evaluated using Student’s t test. A P value of 
0.01 was considered
statistically significant. All analysis was done using Microsoft Excel.
RESULTS
Identificationof additional phenothiazine-likeHCV inhibitors.
Since phenothiazines and like compounds have been used exten-
sively in humans, we first explored the anti-HCV activities of 6
additional FDA-approved phenothiazine and similar compounds
by using a Gluc HCVcc assay (Table 1). All tested compounds
exhibited anti-HCV activity at submicromolar to micromolar
concentrations and were able to specifically inhibit HCV entry
(see Fig. S1 in the supplemental material). The most potent com-
pound, cis-flupentixol, exhibited an IC50 of 0.25 M and a thera-
peutic index (CC50/IC50) of 20. Comparing the anti-HCV poten-
cies of different phenothiazines, we noticed that molecules with a
piperazine ring at position 10 appeared to be slightly more potent
than those with a tertiary amine (prochlorperazine chlorprom-
azine; trifluoperazine and fluphenazine  triflupromazine),
and the presence of a propanol group on the piperazine ring
(fluphenazine) further increased the anti-HCV potency. A tri-
fluoromethyl group at position 2 of the phenothiazine nucleus
also enhanced the overall anti-HCV activity (trifluoperazine
prochlorperazine; triflupromazine  chlorpromazine).
Phenothiazines inhibit HCV fusion. HCV entry involves
three main steps: (i) attachment of virions to the cell surface, (ii)
movement of virus particles from the cell surface to the tight junc-
tion through interaction with different receptors, and (iii) entry
into the host cell through clathrin-mediated endocytosis and fu-
sion of the viral membrane with the endosome upon acidification
(36). To elucidate the anti-HCV mechanism of action of phe-
nothiazines, we first determined the entry step inhibited by phe-
nothiazines in a synchronized infection experiment (Fig. 1A).
Fluphenazine retained maximum entry inhibition when it was
added after the temperature shift to 37°C, indicating that this
compound inhibits a postattachment step of HCV entry. Similar
profiles were obtained for all other phenothiazine inhibitors in a
similar assay using HCVpp (see Fig. S2 in the supplemental mate-
rial). The inhibitory activity of fluphenazinewas lost at a later time
than that of a CD81 antibody (JS81) and at a step similar to that of
inhibition by bafilomycin, an H	-ATPase inhibitor that blocks
the fusion of HCV by suppressing endosome acidification, indi-
cating that fluphenazine and, possibly, other phenothiazines in-
hibit HCV entry at a step later than CD81 binding, likely during
fusion (Fig. 1B).
To determine the effects of phenothiazines on HCV fusion
directly, we carried out an in vitroHCVpp-liposome fusion exper-
iment. For this experiment, we chose fluphenazine and trifluoper-
azine, both phenothiazines with a piperazine substitution at posi-
tion 10, as well as promazine, which has an aliphatic substitution
at this position. All three phenothiazines dose-dependently inhib-
ited HCVpp-liposome fusion in vitro (Fig. 1C), with fluphenazine
exhibiting the strongest fusion inhibition, followed by trifluoper-
azine and promazine, consistent with their anti-HCV potencies
determined via Gluc HCVcc assay (Table 1). This activity was not
due to unspecific molecular quenching of R18 fluorescence (data
not shown) and was therefore fully attributable to fusion inhibi-
tion. These results confirm the fusion-inhibitory activity of these
three phenothiazines. The ability of phenothiazines with both
piperazine and aliphatic substitutions at position 10 to inhibit
HCV fusion suggests that fusion inhibition is independent of the
substitution at position 10 and is likely a feature shared by other
phenothiazines. In addition, since proteins are absent from the
liposome, these data also indicate that a cellular protein(s)/recep-
tor(s) is not required for phenothiazine-mediated HCV fusion
inhibition.
Phenothiazines inhibitHCVfusionbyactingon thehost cell.
We sought to elucidate whether phenothiazines act on cells or the
virus. To determine whether phenothiazines are virucidal, Jc1
Gluc HCVcc was mixed with fluphenazine, prochlorperazine, or
trifluoperazine and then diluted 100-fold (pretreatment), or each
component was first individually diluted and then mixed (con-
trol) (Fig. 2A). The infectivities of HCVcc samples pretreated with
phenothiazines were similar to that observed with the control
(nonpretreated) (Fig. 2B). The positive control, the virucidal
compound PD 404,182, reduced HCV infectivity 90% during
the same period (37). These results indicate that phenothiazines
do not inhibit HCV entry by inactivating the virus directly.
FIG 2 Phenothiazines do not act directly on HCV. (A) Schematics of experi-
ments to determine a compound’s effect on virions. In the pretreatment
group, Jc1 Gluc HCVcc (6.4 105 TCID50/ml) was incubated with the appro-
priate compound at 37°C for 1 h and then diluted 100-fold and used to infect
Huh-7.5 cells. In the control group, the same amounts of HCVcc and drug
were incubated separately at 37°C for 1 h, diluted 100-fold, and thenmixed and
used to infect Huh-7.5 cells. The final titers of HCVcc and the concentrations
of drug were identical between the pretreatment and control groups. (B) Vi-
ruses pretreated with phenothiazines retain similar infectivity to that of the
control. Supernatant Gluc activity was measured at 48 h postinfection and
normalized to the DMSO control (0.5%) level. Fluph, fluphenazine; Triflu,
trifluoperazine; Proch, prochlorperazine; PD, PD 404,182; Bafilo, bafilomy-
cin. The values and error bars represent means and standard deviations, re-
spectively, for at least 2 independent experiments. Statistical significance was
determined by Student’s t test (*, P
 0.01).
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To evaluate whether phenothiazines interact with the host cell,
Huh-7.5 cells were treated with a phenothiazine at 37°C for 2 h
and extensively washed to remove residual drug prior to infection
with Jc1 Gluc HCVcc or VSV-Gpp for 15 min at 0, 4, or 24 h
post-drug removal (Fig. 3A). Cells pretreatedwith phenothiazines
became significantlymore resistant to infection byHCVcc but not
VSV-Gpp, suggesting that phenothiazines inhibit the entry of
HCV by acting on the host cell (Fig. 3B). Cells treated with the
control compound bafilomycin were similarly resistant to both
HCVcc and VSV-Gpp infections. It is worth noting that although
some phenothiazines are able to inhibit clathrin-coated pit forma-
tion and endosome acidification, this effect is likely not at play in
the observed phenothiazine-mediated HCV inhibition phenom-
enon, because inhibition of VSV-Gpp, which also enters cells
through clathrin-mediated endocytosis (38), was not observed at
the same concentration of phenothiazines (Fig. 3B). Collectively,
these results suggest that phenothiazines inhibit HCV entry by
acting on a nonprotein host cell component, likely the lipidmem-
brane.
To confirm that phenothiazines inhibit HCV by interacting
with the target lipidmembrane, we designed amodified liposome-
HCV fusion experiment (Fig. 4A) in which liposomes or virus was
pretreatedwith the appropriate compound prior to dilution of the
mixture and addition of the other component. In set 1, cholester-
ol-rich liposomeswere preincubatedwith phenothiazines (5M).
This mixture was diluted 10-fold to lower the drug concentration
and then mixed with HCVpp. In set 2, HCVpp was preincubated
with phenothiazines (5 M), and the mixture was diluted 10-fold
prior to addition of liposomes. In both sets, the final concentra-
tion of phenothiazine in the mixture was 0.5M, a concentration
that is expected to have little to no effect on liposome-HCVpp
fusion. In set 3, liposomes, phenothiazines (final concentration, 5
M), and HCVpp were all mixed together at the same time. Fi-
nally, in set 4, liposomes andHCVppweremixed in the absence of
phenothiazines.We reasoned that if phenothiazines inhibit HCV-
membrane fusion by interacting with the liposomal membrane,
set 1 (liposomes pretreated with phenothiazine) would exhibit a
similar extent of fusion inhibition to that of set 3 (all components
mixed together), despite the much lower phenothiazine concen-
tration at the time of fusion in set 1, while set 2 (HCVpppretreated
with compound)would exhibitminimal fusion inhibition.On the
other hand, if phenothiazines interact with the virus directly, set 2
would exhibit a similar extent of fusion inhibition to that of set 3.
Stronger fusion inhibition was observed in sets 1 and 3 than in set
2 (Fig. 4B), providing further evidence that phenothiazines inhibit
HCV fusion by acting on the target liposome/cellmembrane. Set 1
exhibited slightly stronger fusion inhibition than set 3, despite the
10-fold lower concentration in set 1 at the time of fusion. Thismay
have been due to the presence of additional vesicles (e.g., exo-
somes) in the concentrated HCVpp samples used in set 3, which
could have competed with R18-labeled liposomes for the phe-
nothiazines during membrane fusion.
Phenothiazines likely inhibit HCV fusion by increasing the
target membrane fluidity. To gain insight into how phenothia-
zines inhibit HCV-membrane fusion, we studied their effect on
lipid membrane fluidity. The lipophilic nature of phenothiazines
enables this class of molecules to intercalate into lipidmembranes
and alter their fluidity (39). However, this effect was never evalu-
ated at low concentrations or inmembranes with high cholesterol
concentrations. Membrane fluidity was gauged by the GP gener-
ated by the fluorescent dyes Laurdan and Prodan. Both Laurdan
and Prodan probes are lipophilic dyes able to insert into lipid
bilayers and become fluorescent. The GP value is higher for rigid/
ordered lipid membranes, as fewer water molecules have access to
the probes embedded inside the membrane (40). The Laurdan
probe inserts deep in the hydrophobic core of the lipidmembrane,
while Prodan preferentially partitions to the lipid head groups
(41).
We determined the effect of phenothiazines on the GP of lipo-
somes composed of 100% POPC or POPC with 30 mol% choles-
terol. Membranes composed of 100% POPC resemble the basal
cellular membrane, while those containing additional cholesterol
mimic lipid raft-containing membranes (42). Phenothiazines sig-
nificantly reduced the GP of cholesterol-rich but not cholesterol-
FIG 3 Phenothiazines inhibit HCV by acting on host cells. (A) Schematic of
experiment to determine whether phenothiazines inhibit HCVcc entry by act-
ing on host cells. Huh-7.5 cells were treated with the specified compounds at
37°C for 2 h, extensively washed at 0 h, and then infected with Jc1 GlucHCVcc
(MOI of1) or VSV-Gpp (diluted 500-fold) for 15 min at 37°C at 0, 4, or 24
h post-compound removal (sets 1 to 3). For set 4, the cells were infected with
the same viruses in the presence of the drugs. (B) Cells pretreated with phe-
nothiazines became resistant toHCVcc but not VSV-Gpp infection, indicating
that phenothiazines selectively inhibit HCV entry. The supernatant Gluc ac-
tivity was measured at 72 h post-drug removal, normalized first to the cell
viability and then to the cell viability-normalized DMSO control (0.5%). The
values and error bars represent means and standard deviations, respectively,
for at least 2 independent experiments. Fluph, 5 M fluphenazine; Triflu, 5
M trifluoperazine; Proch, 5 M prochlorperazine; Bafi, 10 nM bafilomycin.
Statistical significance was determined by Student’s t test (*, P
 0.01).
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free membranes, in a dose-dependent manner (Fig. 5; see Fig. S3
in the supplemental material). These results suggest that phe-
nothiazines specifically reduce the rigidity of cholesterol-rich
membranes. Since similar GP reductions were observed for both
the Laurdan and Prodan dyes, phenothiazines likely insert deep in
the hydrophobic core of the lipid membrane. It is possible that
phenothiazines also intercalate into POPC membranes, but since
these membranes are naturally very fluidic, the presence of phe-
nothiazines does not appear to further increase the membrane
fluidity at the low concentrations used. The ability of phenothia-
FIG 4 Phenothiazines inhibit HCVpp-liposome fusion by interacting with the target membrane. (A) Modified drug addition protocol. Set 1, a phenothiazine
and liposomes were premixed and diluted 10-fold prior to the addition of HCVpp; set 2, HCVpp and a phenothiazine were premixed and diluted 10-fold prior
to the addition of liposomes; set 3, liposomes, a phenothiazine, and HCVpp were mixed together; set 4, liposomes and HCVpp were mixed in the absence of
phenothiazines. The final concentrations of phenothiazines in sets 1 and 2 were 10% of those in set 3. (B) Fusion between HCVpp and liposomes was initiated
by decreasing the pH to 5.0 (time zero) and were recorded as R18 fluorescence dequenching over time. ConcentratedH77HCVpp (2 105 particles) was used
in each assay. Curves representative of at least 4 independent experiments are presented.
FIG 5 Fluphenazine preferentially increases the fluidity of cholesterol-rich membranes. Liposomes composed of pure POPC or POPC with 30% cholesterol
(Cho)were incubatedwith Laurdan (5M)or Prodan (15M) for 15min at room temperature prior to the addition of fluphenazine (5, 10, or 20M)orDMSO
(1.25%). Themixture was incubated at 37°C for another 30min, and the fluorescence shifts were determined. delta GP, GPfluphenazineGPDMSO. The values and
error bars represent means and standard deviations, respectively, for 2 independent experiments.
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zines to significantly reduce the GP of cholesterol-rich but not
cholesterol-freemembranesmay account for theminimal toxicity
at the tested concentrations.We also determined the effect of phe-
nothiazines on liposomes containing both cholesterol and sphin-
gomyelin, a composition that more closely resembles that of lipid
rafts (42). Incorporation of sphingomyelin did not have much
effect on GP reduction (see Fig. S3), suggesting that cholesterol
may be the major effector of phenothiazines. Lipid rafts are be-
lieved to be the location of HCV-cell fusion (32). Collectively, our
data indicate that an increase of lipid raftmembrane fluidity could
be a means through which phenothiazine-induced HCV entry in-
hibition occurs.
Screening for additionalHCV fusion inhibitors.Based on the
above results, we hypothesized that compounds capable of in-
creasing the fluidity of cholesterol-rich membranes will be able to
inhibit HCV entry. We developed a screening assay using choles-
terol-containing liposomes incorporating the Prodan dye and
then screened 2,752 compounds. One compound, topotecan, was
found to preferentially increase the fluidity of cholesterol-rich
membranes at concentrations comparable to those approved for
therapy in humans (43) (Fig. 6A). An in vitro membrane fusion
assay confirmed that topotecan inhibits HCVcc-liposome fusion
(Fig. 6B). This result underscores the importance of membrane
fluidity onHCV entry and validates ourmembrane fluidity-based
screening approach forHCVentry inhibitor discovery. Topotecan
dose-dependently inhibited HCVcc infection in cell culture, with
an estimated EC50 of 0.2M(Fig. 6C) and a CC50 of 88.1M(see
Fig. S4 in the supplemental material). However, the inhibitory
effect of topotecan was due mainly to its inhibition of HCVcc
replication rather than entry (Fig. 7) (see Discussion).
DISCUSSION
Insight into HCV entry gained over the last few years has allowed
for the discovery and development of inhibitors acting at different
stages of viral uptake. Addition of new entry inhibitors to current
therapies will increase the resistance barrier, inhibit expansion of
the infected pool, and reduce the rate and extent of reinfection
after liver transplantation (44). We and others recently identified
3 phenothiazine compounds—trifluoperazine, fluphenazine, and
prochlorperazine—as inhibitors of HCV entry (28, 29). Phe-
nothiazines are a large class of chemicals, many of which are
currently used in clinics to treat psychotic disorders (25). To de-
FIG 6 Characterization of topotecan. (A) Topotecan preferentially increases the fluidity of cholesterol-rich membranes (POPC/Cho/SM) compared to choles-
terol-freemembranes (POPC). Liposomes composed of pure POPCor POPCwith 32mol%cholesterol (Cho) and 14mol% sphingomyelin (SM)were incubated
with Laurdan (5M) or Prodan (15M) for 15 min at room temperature prior to the addition of topotecan (0.1, 0.5, 1, or 2M) or DMSO (1%). The mixture
was incubated at 37°C for another 30 min, and the fluorescence shifts were determined. delta GP, GPtopotecan GPDMSO. The values and error bars represent
means and standard deviations, respectively, for 2 independent experiments. (B) Topotecan dose-dependently inhibits HCVcc-liposome fusion in vitro. HCVcc
(1.6  105 particles) was mixed with R18 dye-labeled liposomes in the presence of increasing concentrations of topotecan. Fusion between HCVcc and
liposomes was triggered by the addition of HCl to lower the solution pH. Dequenching of R18 dye was monitored by determining the increase in fluorescence.
The x axis corresponds to the duration of the process. (C) Topotecan dose-dependently inhibits HCVcc infection in cell culture. The chemical structure of
topotecan is shown in the inset. Huh-7.5 cells were infected with Jc1 Gluc HCVcc (MOI  0.01) in the absence or presence of increasing concentrations of
topotecan. Infectivity (black bars) was quantified by measuring the supernatant Gluc activity at 72 h postinfection and then normalized to the DMSO (0.02%)
control level. Drug cytotoxicity in the absence of HCV infection (solid circles) was determined by the CellTiter-Glo assay. The values and error bars represent
means and standard deviations, respectively, for 2 independent experiments.
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termine whether other phenothiazines can also inhibit HCV in-
fection, we tested 6 additional FDA-approved phenothiazines and
similar molecules and discovered that all these molecules exhibit
anti-HCV activity (Table 1). The most potent inhibitor, cis-
flupentixol, exhibited an IC50 of 0.25 M and a therapeutic index
of 20. The presence of a piperazine ring at position 10 enhances
but is not required for HCV entry inhibition. The presence of a
trifluoromethyl group at position 2 also appears to enhance anti-
HCV activity. This information should assist future structure-ac-
tivity relationship studies to identify more potent phenothiazine-
based anti-HCV inhibitors.
We showed that phenothiazines inhibit HCV-cell fusion by
specifically interacting with the host/target membrane. Incorpo-
ration of phenothiazines into the leaflets of the target membrane
increases the water permeability/fluidity of cholesterol-richmem-
branes (Fig. 5) and reduces the rate of virus-liposome lipidmixing
and hemifusion (Fig. 4). The effects of lipid composition on viral
infection, particularly the influence of cholesterol and sphingolip-
ids, have been studied widely. Many viruses enter host cells via
cholesterol-rich microdomains (lipid rafts), such as West Nile,
Ebola, Marburg, herpes simplex, and vaccinia viruses, retrovi-
ruses, and alphaviruses (45). In some cases, the cholesterol depen-
dence is due to clustering of viral receptors in the lipid raft, while
in other cases it is due to specific interactions between the viral
envelope glycoproteins and (a lipid of) the target membrane, as is
the case for the fusion protein of alphaviruses and cholesterol (46).
Concerning HCV, both phenomena are believed to occur. In vitro
cell culture studies have shown that HCV entry is adversely af-
fected by cholesterol depletion (47, 48). The cholesterol absorp-
tion receptor NPC1L1 was recently identified as an HCV entry
factor (49) which forms cholesterol-enriched microdomains to-
getherwith flotillins (50). Concerning the tetraspaninHCV recep-
tor CD81, two cholesterol binding sites have been mapped in the
three-dimensional model of this molecule (51). It therefore ap-
pears that cholesterol might play a role in HCV entry through the
local mobilization of receptors at specific membrane regions.
Our in vitro fusion studies showed that the presence of choles-
terol significantly enhances the fusion of bothHCV envelope pro-
tein-pseudotyped lentiviruses and cell culture-produced virions
with liposomes, further confirming the important role of choles-
terol in HCV-mediated fusion (32, 33, 52). In these receptor-free
assays, cholesterol is likely to play a direct role in the fusion pro-
cess.
Cholesterol is one of the most important lipid species in eu-
karyotic cells and has several different functions. Two of the pri-
mary and essential roles of cholesterol are to decrease permeability
and increase the stability of the membrane bilayer (53). Mem-
branes rich in cholesterol have a rough surface due to clustering of
cholesterol molecules into small patches (microdomains) (54)
and the different membrane thicknesses of cholesterol-rich re-
gions (55, 56). The local inhomogeneity and curvature in the tar-
get membrane can influence the early interaction of a fusion pro-
tein/peptide with the target membrane and, ultimately, virus
fusion (57, 58). The ability of phenothiazines to significantly in-
crease the fluidity of cholesterol-rich membranes indicates that
these molecules may interfere with cholesterol clustering and de-
crease the packing of cholesterol-rich microdomains, leading to
reduced local inhomogeneity, which is important forHCV fusion.
A second possibility, which is not completely independent of
the first one, is that the incorporation of phenothiazines can affect
interaction of the 3-OH of cholesterol with the HCV envelope
protein/fusion peptide. The 3-OH molecule participates in H-
bond interactions with the head groups of various lipids, water in
the solvent, and membrane proteins. In addition, 3-OH can in-
fluence the folding of peptides at the water-membrane interface
(59). The 3-OH in cholesterol is required for the fusion of Sem-
liki Forest virus (60, 61) and the optimal fusion of HCV with
liposomes (32). Insertion of phenothiazines into the cholesterol-
rich membrane may adversely affect the interaction of 3-OH
with HCV envelope proteins, thus inhibiting HCV-cell fusion.
Building upon our observation that HCV entry can be inhib-
ited by increasing targetmembrane fluidity, we developed a screen
using liposomes and the lipophilic dye Prodan. We screened a
library of 2,752 compounds and identified a molecule, topotecan,
that preferentially increases the fluidity of cholesterol-rich mem-
branes (Fig. 6A). Using a well-established HCVcc-liposome fu-
sion assay (32, 33), we showed that topotecan dose-dependently
inhibitsHCVcc-membrane fusion in vitro, validating the screen as
a tool for discovering inhibitors of virus-cell fusion (Fig. 6B).
However, in cell culture assays, the anti-HCVactivity of topotecan
appears to derive primarily from its inhibition of HCV replication
rather than entry, with an estimated EC50 of 0.2 M (Fig. 7).
Topotecan (Hycamtin) is a topoisomerase I inhibitor that acts by
stabilizing the single-stranded DNA (ssDNA)-topoisomerase I
FIG 7 Topotecan primarily inhibits HCV replication. (A) Effect of topotecan
on HCVcc replication. Huh-7.5 cells were electroporated with Jc1 Gluc HCV
genomic RNA and treated with topotecan, DMSO (0.125%), or 2=CMA at 6 h
postelectroporation. The amount of Gluc reporter in the supernatant and the
intracellular HCV RNA level were quantified at 72 h postelectroporation.
2=CMA, 2=-C-methyladenosine. (B) Topotecan does not inhibit H77 HCVpp
entry. Huh-7.5 cells were transduced with 5-fold-diluted H77 HCVpp or
Envpp in the presence of topotecan, JS81 (2g/ml), or DMSO (0.02%). The
supernatant Gluc reporter activity was measured at 48 h post-compound re-
moval, normalized to signals from Envpp, and used as an indication of the
level of infection. Values represent the means for 2 independent experiments,
and error bars represent the standard deviations.
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complex and causing DNA cleavage (62). It is currently used in
chemotherapy for various cancers. In addition to topoisomerase,
topotecan is known to affect many other cellular pathways, in-
cluding downregulation of the phosphatidylinositol 3-kinase
(PI3K)–Akt signaling pathway (63) and disruption of the hypoxia
inducible factor 1 (HIF-1) signaling pathway (64). Topotecan is
also a substrate of the ABC transporters P-glycoprotein (P-gp/
MDR1) and breast cancer resistance protein (BCRP) and is ac-
tively cleared by the cell (65). The lack of HCV entry inhibition by
topotecan in cell culture assaysmay be due in part to active cellular
extrusion and/or intracellular trafficking of the compound. Nev-
ertheless, the ability of topotecan to inhibit HCV replication may
warrant additional clinical studies of this compound.
In conclusion, our studies shed light on the mechanism of ac-
tion of phenothiazines as inhibitors ofHCV entry and showed, for
the first time, that alteration of target host cell membrane fluidity
can inhibit HCV entry. It is possible that the same mechanism is
responsible for the antiviral activities of phenothiazines toward
other viruses, such as inhibiting the budding of measles and her-
pes simplex viruses (27). Based on these insights, we developed a
high-throughput screen for modulators of cholesterol-rich mem-
brane fluidity and screened a library of 2,752 compounds. One hit
from this screen—topotecan—was found to both increase the flu-
idity of cholesterol-richmembranes and inhibit the fusion of these
membranes with HCV. Targeting an entry step independent of
viral proteins may also be an effective way to retard the develop-
ment of drug resistance and inhibit HCV deletionmutants, which
were found to reduce the antiviral effects of interferon therapy for
chronic hepatitis C patients (66). This study represents an exciting
new paradigm for exploring additional membrane-targeting anti-
virals.
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